期刊文献+

大肠埃希菌耐药性及ESBLs、AmpC酶检测临床分析 被引量:1

Detection on the drug resistance of Escherichia coli and analysis the incidence of ESBLs and AMPC enzyme
下载PDF
导出
摘要 目的研究笔者所在医院2008年1月至2008年12月临床分离的大肠埃希菌耐药性及产超广谱β内酰胺酶(ESBLs)和质粒(AmpC)酶的发生率。方法收集笔者所在医院2008年1月至2008年12月大肠埃希菌53株,用K-B法测定细菌对头孢他啶等17种抗菌药物的敏感性,采用头孢西丁改良三维试验检测ESBLs和AmpC酶。结果 53株大肠埃希菌对美罗培南、亚胺培南、哌拉西林/他唑巴坦、头孢哌酮/舒巴坦、阿米卡星、头孢美唑、头孢西丁、头孢他啶、头孢吡肟的耐药率在0%~18.9%,对其他抗生素耐药率在30.2%~71.7%。53株大肠埃希菌中,24株ESBLs阳性,检出率为45.3%;4株AmpC酶阳性,检出率为7.5%。结论笔者所在医院ESBLs发生率较高,产ESBLs是大肠埃希菌对多种抗生素耐药的主要原因。 Objective To study on the drug resistance of clinically isolated Escherichia coil and analysis the incidence of ESBLs,AMPC enzyme production in our hospital during January,2008 - December,2008. Methods 53 escherichiacoli were collected in in our hospital during January, 2008 - December,2008. The bacterial sensitivity to 17 kinds of antibiotics including ceftazidime was determined by K - B method and the ESBLs ,AMPC enzymes were determined improved eefoxitin three - dimensional test. Results The drug resistance of 53 Eseherichia eoli is about 0 - 18.9% to Meropenem, imipenem, piperacillin / tazobaetam, cefoperazone / sulbactam, amikaein, cefmetazole, cefoxitin, ceftazidime, cefepime. In contrast, the bacterial drug resistance is about 30.2% -71.7% to other antibiotics. In 53 escheriehia coli eases, 24 ESBLs is positive with 45.3% detection rate and the positive rate of 4 AMPC is 7.5%. Conclusion The ESBLs production of escherichia coli is high in our hospital, which is the main reason of multiple antibiotics resistance.
作者 李树旺
出处 《中国医学创新》 CAS 2009年第29期30-31,共2页 Medical Innovation of China
关键词 大肠埃希菌 超广谱Β-内酰胺酶 AMPC酶 耐药性 Escherichia cull Ultra spectrum β -lactamase AamC enzyme Resistance
  • 相关文献

参考文献6

二级参考文献20

  • 1宋玮,唐英春,陆坚,朱家馨,张永标,谈淑卿.产质粒介导Ⅰ型头孢菌素酶细菌的耐药性及基因型研究[J].中华结核和呼吸杂志,2003,26(11):697-700. 被引量:17
  • 2沈定霞,罗燕萍,张秀菊,周光.肺炎克雷伯菌质粒携带DHA-1型ampC基因的克隆和序列分析[J].中华检验医学杂志,2005,28(3):318-318. 被引量:14
  • 3Philippon A,Arlet G,Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother,2002,46:1-11.
  • 4Bauernfeind A,Chong Y,Schweighart S. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection,1989,17:316-321.
  • 5National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 10th informational supplement (aerobic dilution),2002,M100-S10.
  • 6Thomson KS,Sanders CC. Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae:comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother,1992,36:1877-1882.
  • 7Sanders CC,Sanders WE Jr,Moland ES. Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother,1986,30:951-952.
  • 8Perez-Perez FJ,Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol,2002,40:2153-2162.
  • 9Moland ES,Black JA,Ourada J,et al. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother,2002,46:3837-3842.
  • 10Barnaud G,Arlet G,Verdet C,et al. Salmonella enteritidis:AmpC plasmid-mediated inducible beta-lactamase (DHA-1) with an ampR gene from Morganella morganii. Antimicrob Agents Chemother,1998,42:2352-2358.

共引文献238

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部